Commercial Insight: Antihormonal Therapy Cancer Brands - Careful Lifecycle Management

By Author: Manjula Menon
Total Articles: 1486
Comment this article

Antihormonal therapies are a class of cancer therapeutics that generated branded drug sales of $5.8 billion in the seven major pharmaceutical markets in 2007. However, the relative maturity of the market means that it is has become a highly genericized therapeutic class. Even still, the lack of innovation within this saturated market helps many leading brands retain their success.

Scope of this report

Analysis of the performance of each of the antihormonal therapy cancer brands in the seven major markets, forecast to 2017

Analysis and segmentation of the market at various levels including drug class, indication, company and sales growth rate

Assessment of the leading cancer brands and drug classes to identify key success factors within this sector

Quantification of the market size of the antihormonal therapy cancer brands in the seven major pharmaceutical markets with a rest of world snapshot

Research and analysis highlights

The antihormonal therapy cancer brands market was worth $5.8 billion in 2007and is forecast to decline in sales to $5.2 billion by 2017. Factors limiting ...
... market growth include patent expirations, the increasing entry of generic competitors onto the market and the interchangeable nature of some brands within each class.

As a class, the aromatase inhibitor brands achieved higher sales than the luteinizing hormone-releasing hormone analog, anti-androgen or anti-estrogen brands in 2007, achieving $2.4 billion in the seven major pharmaceutical markets. The success enjoyed by the aromatase inhibitors can be attributed, in part, to their favorable side effect profile.

Thirteen differently sized pharmaceutical companies are involved in the development of currently approved antihormonal therapy cancer brands. AstraZeneca leads market, with five out of the 11 brands and includes the leading aromatase inhibitor brand Arimidex.

Key reasons to read this report

Quantify the performance of each of the marketed antihormonal therapy cancer brands in the seven major markets over the period 2007 to 2017

Acquire a detailed account of antihormonal therapy cancer brand dynamics and the events that drive and limit their market growth

Benchmark the antihormonal therapy cancer brands against their generic products and align their 7MM performance with a rest of world snapshot

For more information Kindly visit the website : http://www.bharatbook.com/detail.asp?id=82014

Or Contact us on :
Tel No : (+9122 )27578668 , 27579438
Fax: (+9122 )27579131

Address :
Bharat Book Bureau,
207,Hermes Atrium,
Sector-11
P.O Box 54,
CBD Belapur,
Navi Mumbai - 400614.

Bharat BooK Bureau is the leading market research information aggregator which provides reports, Company profiles, newletters, country info. and online databases for the past twenty years to corportate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Bharat Book Bureau provides strategic information tools to the executives, business analysts, and knowledge managers that will help them to probe into and support critical, timely business decisions and strategies. It helps global companies to know different market before starting up business / expanding in different countries across the world. www.bharatbook.com is one stop shop for the business intelligence information requirements.